Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy.
Department of Experimental, Diagnostic and Specialty Medicine (DIMES), University of Bologna, Bologna, Italy; Sant'Orsola-Malpighi Hospital, Bologna, Italy.
Cancer Lett. 2018 Apr 10;419:84-95. doi: 10.1016/j.canlet.2018.01.049. Epub 2018 Jan 31.
A cancer cell is the final product of a complex mixture of genetic, epigenetic and epitranscriptomic alterations, whose final interplay contribute to cancer onset and progression. This is specifically true for colorectal cancer, a tumor with a strong epigenetic component, which acts earlier than any other genetic alteration in promoting cancer cell malignant transformation. The pattern of progressive, and usually subtype-specific, DNA and histone modifications that occur in colorectal cancer has been extensively studied in the last decade, providing plenty of data to explore. For this tumor, it became recently evident that also RNA modifications play a relevant role in the activation of oncogenes or repression of tumor suppressor genes. In this review we provide a brief overview of all epigenetic and epitranscriptomic changes that have been found associated to colorectal cancer till now. We explore the impact of these alterations in cancer prognosis and response to treatment and discuss their potential use as cancer biomarkers.
癌细胞是遗传、表观遗传和转录后修饰复杂混合的最终产物,其最终相互作用导致癌症的发生和发展。结直肠癌就是一个典型的例子,它是一种具有强烈表观遗传成分的肿瘤,其在促进癌细胞恶性转化方面比任何其他遗传改变都更早发生。在过去的十年中,人们广泛研究了结直肠癌中逐渐发生的、通常是亚型特异性的 DNA 和组蛋白修饰模式,为进一步研究提供了大量数据。最近人们发现,结直肠癌中 RNA 修饰也在癌基因的激活或肿瘤抑制基因的失活中发挥重要作用。在这篇综述中,我们简要概述了迄今为止与结直肠癌相关的所有表观遗传和转录后修饰变化。我们探讨了这些改变对癌症预后和治疗反应的影响,并讨论了它们作为癌症生物标志物的潜在用途。